Table 1.
Clinical characteristics and biochemistry of whole cohort (N = 100)
| Male gender | 60 |
| Age (years) | 51 (46–56) |
| Aortic valve calcification (%) | 100 |
| Mild aortic valve calcification (%) | 32 |
| Moderate aortic valve calcification (%) | 68 |
| Mitral valve calcification (%) | 96 |
| Wilkins score = 0 (N) | 4 |
| Wilkins score = 1 (N) | 61 |
| Wilkins score = 2 (N) | 34 |
| Wilkins score = 3 (N) | 1 |
| Hypertension (%) | 88 |
| Diabetes (%) | 10 |
| eGFR (ml/min) | 28.8 (27.8–30.0) |
| Stage 3 CKD (%) | 33 |
| Stage 4 CKD (%) | 67 |
| Serum phosphorus (mg/dL) | 4.3 (4.2–4.4) |
| Serum phosphorus within normal range (%) | 81 |
| Low serum phosphorus (%) | 19 |
| Serum calcium (mg/dL) | 9.2 (8.9–9.4) |
| Serum calcium within normal range (%) | 100 |
| i-PTH (pg/mL) | 59 (54.0–65.9) |
| Low PTH (%) | 1 |
| High PTH (%) | 4 |
| Serum vitamin D (ng/mL) | 32.0 (23.0–48.0) |
| Vitamin D insufficiency (%) | 47 |
| Vitamin D deficiency (%) | 1 |
| Klotho (pg/mL) | 895.0 (811.0–985.0) |
| FGF-23 (ng/mL) | 10.3 (9.1–11.0) |
| Phosphaturia (mg/24H) | 980 (870–1250) |
| CRP (mg/L) | 8.0 (7.0–10.7) |
| Calcium channel blockers (%) | 31 |
| Calcium channel blockers plus beta blockers (%) | 7 |
| Doxazosin (%) | 5 |
| Calcium channel blockers plus doxazosin (%) | 43 |
Numbers are median and (interquartile range).
i-PTH, intact parathyroid hormone; FGF-23, fibroblast growth factor 23.